SER
Price
$2.22
Change
-$0.28 (-11.20%)
Updated
Sep 11 closing price
Capitalization
56.39M
67 days until earnings call
Intraday BUY SELL Signals
XTLB
Price
$2.47
Change
+$0.07 (+2.92%)
Updated
Sep 11 closing price
Capitalization
6.18M
Intraday BUY SELL Signals
Interact to see
Advertisement

SER vs XTLB

SER vs XTLB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SER vs. XTLB commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SER is a StrongBuy and XTLB is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SER($56.4M) has a higher market cap than XTLB($6.18M). SER YTD gains are higher at: 16.048 vs. XTLB (6.466). XTLB has higher annual earnings (EBITDA): -6.61M vs. SER (-20.5M). SER has more cash in the bank: 23M vs. XTLB (371K). XTLB has less debt than SER: XTLB (86K) vs SER (3.21M). XTLB has higher revenues than SER: XTLB (968K) vs SER (0).
SERXTLBSER / XTLB
Capitalization56.4M6.18M912%
EBITDA-20.5M-6.61M310%
Gain YTD16.0486.466248%
P/E Ratio1.63N/A-
Revenue0968K-
Total Cash23M371K6,199%
Total Debt3.21M86K3,731%
FUNDAMENTALS RATINGS
SER vs XTLB: Fundamental Ratings
SER
XTLB
OUTLOOK RATING
1..100
9594
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4462
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XTLB's Valuation (53) in the Biotechnology industry is in the same range as SER (54) in the null industry. This means that XTLB’s stock grew similarly to SER’s over the last 12 months.

SER's Profit vs Risk Rating (95) in the null industry is in the same range as XTLB (100) in the Biotechnology industry. This means that SER’s stock grew similarly to XTLB’s over the last 12 months.

SER's SMR Rating (100) in the null industry is in the same range as XTLB (100) in the Biotechnology industry. This means that SER’s stock grew similarly to XTLB’s over the last 12 months.

SER's Price Growth Rating (44) in the null industry is in the same range as XTLB (62) in the Biotechnology industry. This means that SER’s stock grew similarly to XTLB’s over the last 12 months.

XTLB's P/E Growth Rating (99) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that XTLB’s stock grew similarly to SER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SERXTLB
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 26 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (SER: $2.22 vs. XTLB: $2.47)
Brand notoriety: SER and XTLB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SER: 126% vs. XTLB: 33%
Market capitalization -- SER: $56.39M vs. XTLB: $6.18M
SER [@Biotechnology] is valued at $56.39M. XTLB’s [@Biotechnology] market capitalization is $6.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SER’s FA Score shows that 0 FA rating(s) are green while XTLB’s FA Score has 0 green FA rating(s).

  • SER’s FA Score: 0 green, 5 red.
  • XTLB’s FA Score: 0 green, 5 red.
According to our system of comparison, SER is a better buy in the long-term than XTLB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SER’s TA Score shows that 5 TA indicator(s) are bullish while XTLB’s TA Score has 2 bullish TA indicator(s).

  • SER’s TA Score: 5 bullish, 5 bearish.
  • XTLB’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, SER is a better buy in the short-term than XTLB.

Price Growth

SER (@Biotechnology) experienced а -18.68% price change this week, while XTLB (@Biotechnology) price change was -1.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

SER is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
SER
Daily Signal:
Gain/Loss:
XTLB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NSBCX62.08N/A
N/A
Nuveen Dividend Growth C
PAREX12.25N/A
N/A
T. Rowe Price Real Estate Advisor
NWABX29.49N/A
N/A
Nationwide R6
ETLCX16.20N/A
N/A
Eventide Large Cap Focus C
RALOX11.79N/A
N/A
Lazard Real Assets Open

SER and

Correlation & Price change

A.I.dvisor indicates that over the last year, SER has been loosely correlated with GERN. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SER jumps, then GERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SER
1D Price
Change %
SER100%
-11.20%
GERN - SER
65%
Loosely correlated
-1.46%
XTLB - SER
59%
Loosely correlated
+2.92%
ELVN - SER
37%
Loosely correlated
-3.40%
TOVX - SER
34%
Loosely correlated
+2.02%
LIFE - SER
34%
Loosely correlated
+3.60%
More

XTLB and

Correlation & Price change

A.I.dvisor indicates that over the last year, XTLB has been loosely correlated with SER. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XTLB jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTLB
1D Price
Change %
XTLB100%
+2.92%
SER - XTLB
59%
Loosely correlated
-11.20%
XBIO - XTLB
36%
Loosely correlated
-4.18%
LIFE - XTLB
31%
Poorly correlated
+3.60%
UNCY - XTLB
28%
Poorly correlated
-0.38%
ANRO - XTLB
27%
Poorly correlated
+1.01%
More